cd62l

Dexamethasone is a glucocorticoid receptor agonist and IL receptor modulator with anti-inflammatory, immunosuppressive, and apoptosis-inducing activities. It inhibits the production of inflammatory miRNA-155 exosomes in macrophages, significantly reduces inflammatory cytokine expression in neutrophils and monocytes, suppresses LPS-induced macrophage inflammation, and induces autophagy. It is commonly used to induce animal models of depression, muscle atrophy, and hypertension, and holds potential in COVID-19 research.

Anti-Mouse L-Selectin/CD62L Antibody (Mel-14) is a rat-derived IgG2a, κ antibody inhibitor targeting mouse L-Selectin/CD62L.

Dexamethasone-d3-1 (Hexadecadrol-d3-1; Prednisolone F-d3-1) is a deuterium-labeled form of Dexamethasone. Dexamethasone (Hexadecadrol) acts as an agonist of the glucocorticoid receptor and effectively reduces the expression of CD11b, CD18, and CD62L on neutrophils, as well as CD11b and CD18 on monocytes. It holds potential for research on COVID-19. In LPS-induced macrophage inflammatory responses, Dexamethasone inhibits the production of exosomes containing inflammatory miRNA-155.

Dexamethasone-4,6α,21,21-d4 is the deuterated derivative of Dexamethasone-4,6α,21,21. Dexamethasone (Hexadecadrol) functions as an agonist of the glucocorticoid receptor. It notably reduces the expression of CD11b, CD18, and CD62L on neutrophils, as well as CD11b and CD18 on monocytes. Dexamethasone shows potential for research related to COVID-19.